Physician profile
Lori Blake
NPI 1255397220
$398.82
in general payments reported to CMS, 2019-2025
11 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.40 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $130.86 | 2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $52.31 | 2025 | Fasenra, Airsupra, Farxiga |
| Astellas Pharma US INC | $44.17 | 2025 | Veozah |
| Exact Sciences Corporation | $35.25 | 2025 | The Cologuard Plus Collection Kit |
| Abbvie INC. | $24.53 | 2025 | |
| Globus Medical, INC. | $20.83 | 2025 | Senza |
| Dexcom, INC. | $19.31 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $19.20 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $17.87 | 2025 | Rexulti |
| Boston Scientific Corporation | $17.40 | 2022 | |
| Resmed Corp | $17.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.